)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Bioatla (BCAB) investor relations material
Bioatla Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Advanced clinical progress for BA3182 (EpCAM x CD3 TCE) and Ozuriftamab vedotin (Oz-V), with tumor reductions and stable disease in solid tumors and high response rates in HPV+ OPSCC; key data readouts expected in 2H 2025 and 1H 2026.
Mecbotamab vedotin and evalstotug show promising survival, safety, and efficacy in difficult-to-treat cancers, including mKRAS NSCLC and metastatic melanoma.
Strategic partnerships and collaborations are progressing, with at least one term sheet in place and transactions expected to close in 2025.
No product revenue recognized; company remains in clinical-stage development with no approved products.
Net loss for Q2 2025 was $18.7M, down from $21.1M in Q2 2024; cash and equivalents at June 30, 2025, were $18.2M.
Financial highlights
R&D expenses for Q2 2025 were $13.7M, down from $16.2M year-over-year, mainly due to workforce reduction and program prioritization.
G&A expenses decreased to $5.0M from $5.8M year-over-year, reflecting lower stock-based compensation and headcount.
Net cash used in operations for H1 2025 was $30.4M, down from $50.0M in H1 2024.
Net loss per share for Q2 2025 was $0.32, improved from $0.44 in Q2 2024; weighted-average shares outstanding were 58.5M.
Total stockholders' equity was $(16.7)M as of June 30, 2025, down from $14.3M at year-end 2024.
Outlook and guidance
Phase I data readout for BA3182 expected in 2H 2025, with expansion data in 2026.
FDA meeting for Oz-V Phase 3 design in 2L+ HPV+ SCCHN scheduled for Q3 2025; pivotal trial to follow.
R&D and cash burn expected to decrease as Phase II trials close and focus shifts to prioritized programs.
Additional capital will be required to fund operations beyond the first half of 2026; management is exploring equity, debt, and strategic transactions.
No meaningful product revenue expected in the foreseeable future.
What asset is at term sheet stage for partnering?
What is the planned Oz-V Phase III trial design?
Which indication for EpCAM expansion cohort?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Bioatla earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Bioatla Inc is a clinical-stage biopharmaceutical company specializing in the development of novel monoclonal antibody and cell-based therapeutics for the treatment of solid tumor cancers. Utilizing its proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms, Bioatla is focused on creating therapies with improved selectivity for the tumor microenvironment, potentially enhancing safety and therapeutic efficacy. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage